| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland
Mismatch repair (MMR) deficiency was reported to increase resistance of mammalian cells to killing by several genotoxic substances. However, although MMR-deficient cells are 
100-fold more resistant to killing by SN1 type methylating agents than MMR-proficient controls, the sensitivity differences reported for the other agents were typically <2-fold. To test whether these differences were linked to factors other than MMR status, we studied the cytotoxicities of mitomycin C, chloroethylcyclohexyl nitrosourea, melphalan, psoralen-UVA, etoposide, camptothecin, ionizing radiation, and cis-dichlorodiaminoplatinum (cisplatin) in a strictly isogenic system. We now report that MMR deficiency reproducibly desensitized cells solely to cisplatin.
This article has been cited by other articles:
|
|
 |
|
  R. P. Topping, J. C. Wilkinson, and K. D. Scarpinato Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling J. Biol. Chem., May 22, 2009; 284(21): 14029 - 14039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hong, J. Jiang, K. Hashiguchi, M. Hoshi, L. Lan, and A. Yasui Recruitment of mismatch repair proteins to the site of DNA damage in human cells J. Cell Sci., October 1, 2008; 121(19): 3146 - 3154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rodriguez, L. T. Hansen, G. Phear, J. Scorah, M. Spang-Thomsen, A. Cox, T. Helleday, and M. Meuth Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11 Clin. Cancer Res., September 1, 2008; 14(17): 5476 - 5483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Carethers Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 33 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Reynolds and A. Zhitkovich Cellular vitamin C increases chromate toxicity via a death program requiring mismatch repair but not p53 Carcinogenesis, July 1, 2007; 28(7): 1613 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reynolds, L. Stoddard, I. Bespalov, and A. Zhitkovich Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair Nucleic Acids Res., January 28, 2007; 35(2): 465 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Kennedy and A. D. D'Andrea DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J M Carethers Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut, June 1, 2006; 55(6): 759 - 761. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hunter, R. Smith, D. P. Cahill, P. Stephens, C. Stevens, J. Teague, C. Greenman, S. Edkins, G. Bignell, H. Davies, et al. A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy. Cancer Res., April 15, 2006; 66(8): 3987 - 3991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. O'Brien and R. Brown Signalling cell cycle arrest and cell death through the MMR System Carcinogenesis, April 1, 2006; 27(4): 682 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Peterson-Roth, M. Reynolds, G. Quievryn, and A. Zhitkovich Mismatch Repair Proteins Are Activators of Toxic Responses to Chromium-DNA Damage Mol. Cell. Biol., May 1, 2005; 25(9): 3596 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
